公开(公告)号：EP1114166B1

公开(公告)日：2005-03-23

申请号：EP99942778.4

申请日：1999-09-13

申请人： Pharmexa A/S

发明人： HALKIER, Torben ,  HAANING, Jesper

IPC分类号： C12N15/62 ,  C12N15/86 ,  C12N15/12 ,  C12N5/10 ,  C12N1/21 ,  C12N1/19 ,  C07K14/705 ,  A61K39/00 ,  A61K31/713 ,  G01N33/50

CPC分类号： C07K14/70575 ,  A61K39/00 ,  A61K2039/51 ,  C07K2319/02 ,  C12N2799/021 ,  Y02A50/412

摘要： The invention provides a novel method for down-regulating the biological activity of osteoprotegerin ligand (OPGL, TRANCE) thereby rendering possible the treatment/amelioration of diseases characterized by excessive loss of bone mass, e.g. osteoporosis. Down-regulation is effected by inducing an immune response against OPGL in an individual in need thereof. Immune responses can be raised by classical immunization with immunogenic variants of OPGL or by nucleic acid immunization where the nucleic acids encode the OPGL variant. The invention also pertains to compositions, polypeptides and nucleic acids useful in the invention, as well as to vectors and transformed host cells useful in the preparation thereof.

公开(公告)号：EP1117421B1

公开(公告)日：2004-06-16

申请号：EP99945967.0

申请日：1999-10-05

申请人： Pharmexa A/S

发明人： STEINAA, Lucilla ,  MOURITSEN, Soren ,  NIELSEN, Klaus, Gregorius ,  HAANING, Jesper ,  LEACH, Dana ,  DALUM, Iben ,  GAUTAM, Anand ,  RASMUSSEN BIRK, Peter ,  KARLSSON, Gunilla

IPC分类号： A61K38/17 ,  A61K38/18 ,  C07K14/50 ,  C07K14/705 ,  C07K14/71 ,  C12N15/63 ,  C12N5/16 ,  C12N15/12

CPC分类号： C07K16/3069 ,  A61K39/0011 ,  C07K14/50 ,  C07K14/705 ,  C07K14/70539 ,  C07K14/71 ,  C07K2317/34 ,  C12N2799/021 ,  Y02A50/412

摘要： A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.